3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
111
Neoplasms
8
Neoplasm Metastasis
6
Carcinoma, Intraductal, Noninfiltrating
6
Breast Carcinoma In Situ
4
Arthralgia
4
Advanced Breast Cancer
4
Osteoporosis
2
Multiple Endocrine Neoplasia Type 1
2
Breast Neoplasms, Male
2
Breast Cancer Metastatic
2
Triple Negative Breast Neoplasms
1
Sexual Dysfunction, Physiological
1
Seizures
1
Recurrence
1
Quality of Life
1
Patient Compliance
1
Pain
1
Ovarian Neoplasms
1
Obesity
1
Lethal Congenital Contracture Syndrome 2
1
Joint Diseases
1
Invasive Breast Cancer
1
Hypogonadism
1
Granulosa Cell Ovarian Cancer
1
Fractures, Bone
1
Erectile Dysfunction
1
Epilepsy
1
Bone Diseases, Metabolic
1
Bone Density
1
Interventions
Cyclophosphamide
67
Dexamethasone
52
Peripheral Blood Stem Cell Transplantation
37
Lenalidomide
37
Rituximab
35
fludarabine phosphate
34
Bortezomib
30
Filgrastim
27
Etoposide
27
Cytarabine
25
Carboplatin
25
Busulfan
23
Radiotherapy
22
Melphalan
22
Gemcitabine
22
Cyclosporine
21
pomalidomide
20
fludarabine
20
Whole-Body Irradiation
20
Mycophenolic Acid
20
Paclitaxel
19
Methotrexate
18
venetoclax
17
Cisplatin
17
pembrolizumab
16
Calcium Dobesilate
16
Bevacizumab
16
Tacrolimus
14
Antilymphocyte Serum
14
Nivolumab
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Recurrence
×
Anastrozole
×
Clear all
NCT00256698
2012-08-01
FACT
AstraZeneca
Phase 3
Completed
514 enrolled
13 charts